A Novel Semi-Supervised Algorithm for Rare Prescription Side Effect Discovery
Jenna Reps, Jonathan M. Garibaldi, Uwe Aickelin, Daniele Soria, Jack, E. Gibson, Richard B. Hubbard

TL;DR
This paper introduces a semi-supervised meta-analysis framework that enhances detection of rare drug side effects, outperforming existing methods and potentially improving post-marketing drug safety surveillance.
Contribution
It presents a novel computational framework combining existing techniques, web knowledge, metric learning, and semi-supervised clustering for rare side effect detection.
Findings
Successfully signalled known rare side effects like tendon rupture and renal failure.
Generated signals at more stringent thresholds than existing methods for most drugs.
Demonstrated potential to improve post-marketing surveillance for rare side effects.
Abstract
Drugs are frequently prescribed to patients with the aim of improving each patient's medical state, but an unfortunate consequence of most prescription drugs is the occurrence of undesirable side effects. Side effects that occur in more than one in a thousand patients are likely to be signalled efficiently by current drug surveillance methods, however, these same methods may take decades before generating signals for rarer side effects, risking medical morbidity or mortality in patients prescribed the drug while the rare side effect is undiscovered. In this paper we propose a novel computational meta-analysis framework for signalling rare side effects that integrates existing methods, knowledge from the web, metric learning and semi-supervised clustering. The novel framework was able to signal many known rare and serious side effects for the selection of drugs investigated, such as…
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
